BGI SENTIS™ Comprehensive Hereditary Cancer Panel

BGI SENTIS™ Comprehensive Hereditary Cancer Panel

Introduction

BGI’s hereditary risk screening cancer panels target genes previously linked to a predisposition of cancer. Panel selection was based on expert curation of scientific literature and other high quality resources, including formal medical guidelines.

BGI’s Comprehensive Hereditary Cancer Panel provides information on 79 genes associated with 24 different types of hereditary cancer including some of the most commonly occurring cancers such as hereditary breast, ovarian, colorectal, prostate and stomach cancer. BGI detects different alterations including germline SNV, Indels and CNV.

 

  • SUITABLE FOR:

    Patients suspected of being at increased risk of hereditary cancer

  • TA TIME:

    20 working days

  • SAMPLE:

    Peripheral blood, DNA, Saliva

  • TECHNOLOGY:

    Target region capture, High-throughput sequencing

List of Hereditary Cancers Tested

Hereditary cancers

Female package

Male package

Breast

Ovarian

Prostate

Multiple Endocrine Neoplasia

Thyroid

Parathyroid

Neurofibromatosis

Pheochromocytoma

Familial Paraganglioma

Retinoblastoma

Melanoma

Chondrosarcoma

Colorectal

Pancreatic

Endometrial

Gastric

Renal

Bladder

Gastrointestinal Stromal

Urothelial Carcinoma

Tuberous Sclerosis

Nephroblastoma

Neuroblastoma

Nevoid Basal Cell Carcinoma

Why Choose BGI SENTIS™ Comprehensive Hereditary Cancer Panel?

  • Comprehensive – whole exome plus flanking intronic regions covered for all genes tested; one single assay that detects point mutations, deletions, insertions, duplications, rearrangements
  • Robust – clinically important (pathogenic or likely pathogenic) variants are verified by Sanger Sequencing while large gene rearrangements are verified by qPCR
  • Convenient – test from blood or saliva; DNA is also accepted
  • Professional – state-of-the-art variant database ensures up-to-date analysis and interpretation.

 

Note: this test is considered a screening test, not a diagnostic test. Before making any treatment decisions, all patients should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate. This testing service has not been cleared or approved by the US FDA and is not available in the USA.

Workflow

Ordering the BGI SENTIS™ Comprehensive Hereditary Cancer Panel is easy.

  • STEP 1

    Physician orders test

  • STEP 2

    Blood or saliva sample collected

  • STEP 3

    Sample shipped to BGI and analyzed

  • STEP 4

    Results sent to physician

Quick Contact